2177GCCC:ID'Ing tx Targets and Biomarkers for Ocular Surface Disease in Pt w/ oGVHD

Part of paid clinical trials in Baltimore, Maryland.

Sponsor
University of Maryland, Baltimore
Study ID
NCT04946721
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • The standard care exam and biological specimens' collection — DIAGNOSTIC_TEST
    During each visit, in addition to standard of care exams, certain biological specimens ( ocular surface wash, mucocellular material, corneal filaments or impression cytology of conjunctiva, blood or serum) will be collected.

Study Details

Evaluate and study the immunologic changes to the ocular surface in cancer patients.

Key Dates

Start date
Apr 27, 2022
Status verified
Jan 2026
Primary completion
Dec 31, 2027
Completion
Dec 31, 2027

Study Design

Enrollment
150 participants (estimated)

Arms

  • Arm: 1.BMT Patients (Study)
    Patients prior to receiving a bone marrow transplant will be recruited during their initial intake prior to their BM transplant through the PI's regularly scheduled appointment with these patients.
  • Arm: 2.Controls
    Patients with no history of eye disease or cancer history

Primary Outcome Measure

1. Risk factors and markers for developing eye diseases [ Time Frame: Up to 4 years ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Geenebaum Cancer Center, University of Maryland Medical CenterBaltimoreMaryland21201
Patricia Lesho
[email protected]
410-328-2577

Find similar trials in Baltimore, MD

By research site
Geenebaum Cancer Center, University of Maryland Medical Center· Baltimore, MD

Related Studies